Information was received from a healthcare professional (hcp) via a clinical study and a manufacturer representative (rep) regarding a patient receiving remodulin (unknown dose and concentration) via an implantable pump.
It was reported there was a device malfunction where the expected residual volume was 9.
2 ml and the actual residual volume was 17.
9ml.
The pump accuracy was 72% and the flow rate was outside the expected range.
The patient reported no symptoms and there was no impact to the patient.
There was no additional medical intervention required to prevent permanent injury or impairment and no action was taken.
No assessment for product/therapy/procedure relatedness was performed.
The patient's medical history included dyspnea / shortness of breath - on exertion, exercise intolerance, palpitations, orthopnea, congenital heart disease, hypertension, pulmonary hypertension (ph), syncope, due to unknown etiology, valve dysfunction, aortic, valve dysfunction, mitral, valve dysfunction, tricuspid, valve dysfunction, pulmonary, cor pulmonale, intrapulmonary shunting, renal dysfunction, not requiring dialysis, obesity, peripheral edema, sleep apnea, pneumonia, left upper lobe calcified granuloma, fibromyalgia, hysterectomy, back surgery, bacteremia (groshong catheter infection), dizziness, pre-syncope, jaw pain, headache, nausea, and chest pain.
The event date was (b)(6) 2021.
Additional information received from a rep indicated there was no resolution for this particular incident and no action was taken.
In regards to the cause, it was noted it was unknown and was being investigated.
No further complications were reported/anticipated.
|